Addendum No. 05 with Written Inquiry Responses
DCF RFP 2627 020
EMERGENCY OPIOID ANTAGONIST PRODUCTS & RESOURCES
SUBSTANCE ABUSE AND MENTAL HEALTH

Solicitation Number: DCF RFP 2627 020

Solicitation Title: EMERGENCY OPIOID ANTAGONIST PRODUCTS & RESOURCES

Response(s) Due Date: 10/05/2026

Addendum Number: 05

Addendum Date: 09/21/2026

FAILURE TO FILE A PROTEST WITHIN THE TIME PRESCRIBED IN SECTION 120.57(3), FLORIDA STATUTES, OR FAILURE TO POST THE BOND OR OTHER SECURITY REQUIRED BY LAW WITHIN THE TIME ALLOWED FOR FILING A BOND SHALL CONSTITUTE A WAIVER OF PROCEEDINGS UNDER CHAPTER 120, FLORIDA STATUTES.

DCF RFP 2627 020 *is hereby amended as follows, all other terms and conditions of the solicitation remain in effect. All additions are highlighted in yellow, and words ~~stricken~~ are deletions:*

Change No. 1

PO Scope of Work, Section 4.1.2 and 4.1.3

4.1.2 The Department's Purchase Order Terms and Conditions, located at:
~~https://www.myflfamilies.com/general-information/contracted-client-services/library.~~
https://www.myflfamilies.com/about/additional-services-offices/contracted-client-services/resources/

4.1.3 Department of Children and Families Standard Contract Definitions, located at:
~~https://www.myflfamilies.com/general-information/contracted-client-services/library~~
https://www.myflfamilies.com/about/additional-services-offices/contracted-client-services/resources/

Change No. 2

Appendix V, Cost Proposal

PRODUCT	DOSAGE	QUANTITY	COST/KIT
~~Intranasal Emergency Opioid Antagonist Product~~	~~2.7mg~~	~~2 doses per kit~~	~~$~~
Intranasal Emergency Opioid Antagonist Product	3mg	2 doses per kit	$
Intranasal Emergency Opioid Antagonist Product	4mg	2 doses per kit	$
Intranasal Emergency Opioid Antagonist Product	8mg	2 doses per kit	$

Luer Lock	Any ml	Prefilled syringe	$
Prefilled Syringe with Attached Needle for Intramuscular Injection	Any ml	Prefilled syringe	$
Auto-Injector (prophylactic use only)	10mg	Unit	$
Vial	Any ml	Unit	$

Change No. 03

PO Scope of Work, Section 5.3.5.5.

PRODUCT	DOSAGE	QUANTITY
~~Intranasal Emergency Opioid Antagonist Product~~	~~2.7mg~~	~~2 doses per kit~~
Intranasal Emergency Opioid Antagonist Product	3mg	2 doses per kit
Intranasal Emergency Opioid Antagonist Product	4mg	2 doses per kit
Intranasal Emergency Opioid Antagonist Product	8mg	2 doses per kit
Luer Lock	Any ml	Prefilled syringe
Prefilled Syringe with Attached Needle for Intramuscular Injection	Any ml	Prefilled syringe
Auto-Injector (prophylactic use only)	10mg	Unit
Vial	Any ml	Unit
Emergency Opioid Antagonist related informational stickers, posters, flyers, informational sheets, signs, demonstrational devices, and educational materials.	N/A	As needed to include with product shipments.

Change No. 04

RFP Template, Section 5.2.2 Financial Scoring

A formula will be used to evaluate the financial portion for this solicitation. The maximum number of points for the financial score is 40 points. The formula used is as follows:

(N/X) x Y = Z

Where:

N = Lowest responsive cost received for ~~all Responses~~ the applicable product

X = Respondent's costs for the applicable product

Y = Maximum possible financial points

Z = Financial points awarded for the applicable product

Financial scores will be calculated separately for each product. Costs associated with different products will not be combined when calculating the financial score for an individual product.

Total Score of Responses

~~The Procurement Officer will average the total scores. The Procurement Officer will use the total points to rank Respondents. This ranking will serve as the recommended ranking of the Department's Evaluators.~~ For each product, the Respondent's total score will consist of the applicable programmatic evaluation score and the financial score calculated for that product. Respondents will be ranked separately for each product based on their applicable total scores. The Procurement Officer will use the product-specific rankings to develop the recommended ranking for each product.

Change No. 05

RFP Template, Section 1.3, Term of the Agreement

The anticipated start date of the resulting Contract(s) is ~~no later than~~ November ~~30~~ 20, 2026. The anticipated duration of the Contract is one (1) year. Renewal, if any, shall comply with §287.057(14), F.S.

Change No. 06

PO Scope of Work, Section 5.3.5.1

The Provider must have the capability to implement ~~enable~~ QR-code tracking of distributed kits, should the Department elect to implement this approach. The Department is not requiring implementation or use of QR-code tracking at this time. If implemented, the ~~by including a~~ QR code ~~to~~ capability must be capable of ~~accompany each package that records~~ recording the recipient and the zip code of ~~distribution~~ administration. Information gathered through the QR code shall be specific to services funded under the resulting purchase order. Emergency Opioid Antagonist Products must provide at least 30 months of shelf-life remaining at the documented date of shipment. The Department will receive the most recently manufactured product available in each shipment.

Change No. 07

Appendix II

As the person named in the Certificate of Signature Authority as the Authorized Representative of the Respondent, _____ (legal name of Vendor), I confirm that I have fully informed myself of all terms and conditions of solicitation # DCF RFP ~~2526 018~~ 2627 020 (the solicitation), the facts regarding the Response submitted by the Vendor in response to the solicitation and the truth of each statement contained in Certifications (a) through (f) and certify, by checking the applicable "true" or "false" box below and affixing my signature hereto, that each statement in each checked certification is "true" or "false" as indicated.

Change No. 08

PO Scope of Work, Section 3.3, Term

~~The total term (original term and renewal term) of the resulting Contract will be limited to the remaining term of the Providers' Alternate Contract Source contract, unless the Provider's contract includes duration or survivability language that permits the Department to contract with the Provider past the expiration.~~

PO Scope of Work, Section 4.2, Composition of the Contract

~~Notwithstanding the order of precedence indicated, for purchases based on a state term contract or an enterprise alternative contract source procured for state agency use by the Department of Management Services, the terms of the underlying state term contract or Department of Management Services enterprise alternative contract source agreement shall prevail over conflicting terms in other documents in the order of precedence, unless by the terms of that underlying state term contract or alternative contract source agreement the "Customer" is explicitly authorized to vary the terms to the State's detriment.~~

Change No. 09

PO Scope of Work, Section 5.3.1.3, Shipping and Delivery

Stickers, posters, flyers, informational sheets, signs, demonstrational devices, and educational materials must be available in at minimum, English, Spanish, and Haitian Creole. These items must be available through the vendor portal at no cost to the enrolled distributor or the Department. Required physical copies of these items must also be provided at no additional cost when requested by the Department or needed for inclusion with product shipments.

Response to Written Inquiries:

Question #	Vendor Name	Solicitation Section	Question	Department Response
1.	McKesson Medical-Surgical Government Solutions LLC	DCF RFP 2627 020, 4.2.5 Response Section 4: Core Team Qualifications / PO Scope of Work Reference, 10	Section 4.2.5.3 requests that Respondents describe their operational approach to the recruitment, training, supervision, and retention of qualified personnel "as described in the PO Scope of Work." We were unable to locate specific requirements in the PO Scope of Work related to recruitment, supervision, training, retention, staffing levels, or personnel qualifications, other than the Account Manager requirements in Section 5.3.2. Please clarify whether there are additional personnel-related requirements that Respondents should address in this section, or whether Respondents should describe their organization's standard practices for recruitment, training, supervision, and retention in support of the services described in the Scope of Work?	Respondents should address the personnel requirements identified in **Sections 4.2.5.3** and **4.2.5.4** of the RFP, including their operational approach to recruitment, training, supervision, retention, personnel grievance and conflict resolution practices, organizational structure, subcontractors, staffing levels, and qualifications of key professional-level personnel. Respondents may describe their standard organizational practices to demonstrate how those practices will support successful performance of the Scope of Work.
2.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 2. Governance and 2.1, 1	Please provide all applicable terms, conditions, and requirements as detailed within these sections.	The Provider shall comply with the applicable terms, conditions, and requirements identified in PO Scope of Work **Sections 2** and **2.1**, including all applicable state and federal requirements and the terms, conditions, and limitations of the State Opioid Response (SOR) Grant applicable to the resulting Contract.
3.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 2. Governance and 2.1, 1	Please provide the referenced State Opioid Response Grant terms, conditions and limitations.	The SOR Grant requirements applicable to the resulting Contract include applicable grant management requirements, financial and performance reporting, allowable costs, and audit

Question #	Vendor Name	Solicitation Section	Question	Department Response
				requirements, as well as applicable federal requirements. Respondents are responsible for complying with all applicable requirements associated with the funding source.
4.	McKesson Medical-Surgical Government Solutions LLC	DCF RFP 2627 020, 4.2.5 Response Section 4: Core Team Qualifications, 9	Section 4.2.5.1 requests Respondents to include "résumés for key leadership personnel." To improve readability and organization of the response, would DCF permit Respondents to provide key leadership résumés in a separate appendix (e.g., Appendix VI: Key Leadership Résumés) rather than within the main narrative of the response?	Yes. Respondents may provide the required key leadership résumés as a separate appendix, provided the résumés are clearly identified and included as part of the Response.
5.	McKesson Medical-Surgical Government Solutions LLC	DCF RFP 2627 020 and Form PUR 1000, 8. Payments, 8.3.6 and 7. Payment, d. Transaction Fee, 10 and 12	Please confirm which transaction fee applies to this solicitation, as the incorporated documents appear to reference both a 0.7% and a 1.0% transaction fee.	The transaction fee applicable to this solicitation is 0.7%, as specified in PO Scope of Work, **Section 8.3.6.** This response does not alter any transaction-fee requirement that is imposed by applicable law or Department of Management Services requirements.
6.	McKesson Medical-Surgical Government Solutions LLC	PUR 1001, Paragraph 4 , 2	Please clarify which solicitation document(s) are considered the “Technical Specifications” for purposes of the order of precedence established in this provision.	The order of precedence applicable to this solicitation is established in **Section 3.2** of the RFP. **Section 3.2** provides that, in the event of a conflict, the order of priority is: (1) Addenda to solicitation documents; (2) PO Scope of Work; (3) PO Terms and Conditions; (4) the solicitation and its attachments; and (5) PUR 1001.
7.	McKesson Medical-Surgical Government Solutions LLC	PUR 1001, Paragraph 4 , 2	Please clarify which solicitation document(s) are considered the “Special Conditions and Instructions” for purposes of the order of	See the response to **Question #6**. The order of precedence in the RFP **Section 3.2** governs this solicitation. The categories identified in PUR 1001 do not supersede the solicitation-specific order of precedence.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			precedence established in this provision.	
8.	McKesson Medical-Surgical Government Solutions LLC	PUR 1001, Paragraph 4 , 2	Please clarify which solicitation document(s) are considered the "Introductory Materials" for purposes of the order of precedence established in this provision.	See the response to **Question #6**. The order of precedence in the **RFP Section 3.2** governs this solicitation.
9.	McKesson Medical-Surgical Government Solutions LLC	PUR 1001, Purchase Order Scope of Work, REQUEST FOR PROPOSAL, Paragraph 4, Paragraph 4, Section 3, 2, 1-2, 7-8	Please confirm which order of precedence governs this solicitation and any resulting contract	See the response to **Question 6. RFP Section 3.2** governs the order of precedence for this solicitation. The RFP specifically provides that its terms take precedence over PUR 1001 in the event of a conflict, unless the conflicting PUR 1001 provision is required by Florida law.
10.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 4.1.3, 1	Please provide a copy of the referenced document, as the hyperlink appears to be inaccessible.	Refer to **Change No. 01**.
11.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 5.1, 2	Please provide any available historical data regarding the volume of emergency orders placed under this contract, including the frequency of such orders and the typical turnaround time expected for emergency shipments.	The PO Scope of Work states that Emergency Orders typically occur four to six times per month. Emergency Orders placed by the Department by 4:00 PM EST are required to be fulfilled with overnight shipping at no additional cost. The solicitation does not establish a guaranteed emergency-order quantity, specific order size, or specific destination for pricing purposes.
12.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 5.1, 2	Please provide any available historical data regarding the volume of emergency orders placed under this contract, including the frequency of such orders and the typical	Refer to response to **Question #11**.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			turnaround time expected for emergency shipments.	
13.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 5.3.1.2, 2	Please clarify whether the Department will provide the graphics, artwork, written content, and translations for the stickers, posters, flyers, informational sheets, signs, demonstrational devices, and educational materials required under this section, or whether the awarded contractor will be responsible for developing such materials.	The Provider is responsible for providing the informational and educational resources required by the PO Scope of Work at no cost to the Department or Enrolled Distributors. Materials must be available in English, Spanish, and Haitian Creole. The solicitation does not require the Department to develop or provide the Provider's graphics, artwork, written materials, or translations.
14.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 5.3.5.5., 4	The Product Table includes a 2.7 mg Intranasal Emergency Opioid Antagonist Product. Our understanding is that this product is no longer commercially available. Please confirm that offerors are not required to propose this product to be considered responsive and revise the Product Table accordingly.	Refer to **Change No. 02** and **Change No. 03**.
15.	McKesson Medical-Surgical Government Solutions LLC	Request For Proposal, APPENDIX V: COST PROPOSAL, 21	The Product Table includes a 2.7 mg Intranasal Emergency Opioid Antagonist Product. Our understanding is that this product is no longer commercially available. Please confirm that offerors are not required to propose this product to be considered responsive and revise the Product Table accordingly.	Refer to the response to **Question #14**.
16.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, Deliverable 4: Reports, 7	Please clarify whether compliance with this requirement may be satisfied through anonymized or aggregated reporting, as certain customer agreements prohibit	No. The required reporting must satisfy the specific reporting requirements in the PO Scope of Work. The monthly report must include the information identified in **Section 5.3.4**, including the top ten counties and ZIP codes and the top thirty accounts shipped to

Question #	Vendor Name	Solicitation Section	Question	Department Response
			disclosure of account-specific shipment information.	during the applicable reporting periods. Anonymized or aggregated reporting alone would not satisfy requirements that call for account-level information.
17.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Terms and Conditions, Section 4, A. Indemnification, 3&4	Would the State please revise the indemnification provision to apply only to third-party bodily injury claims resulting from the Contractor's negligence or willful misconduct?	No. The Department will not revise the indemnification provision. Respondents must comply with the Purchase Order Terms and Conditions incorporated into the solicitation.
18.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Terms & Conditions, Section 8. RESPECT and PRIDE., 8-9	Please confirm whether any products or services required under the resulting contract are currently subject to the RESPECT or PRIDE purchasing requirements referenced in Section 8. If so, please identify the specific products or services to which those requirements apply.	The RESPECT and PRIDE requirements apply when a product or service required to perform the Purchase Order is subject to the applicable statutory purchasing requirements. The Provider is responsible for complying with those requirements if applicable to the products or services being provided.
19.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Terms and Conditions, 7.4, 8	Please provide a copy of the referenced document, as the hyperlink appears to be inaccessible.	Refer to **Change No. 01**.
20.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 5.3.5. Product, 5.3.5.1., 4	Please confirm whether the Department requires the use of a QR code specifically, or whether an alternative tracking method, such as standard carrier tracking (e.g., UPS or FedEx tracking), would satisfy this requirement.	The Department is not requiring implementation or use of QR-code tracking at this time. The Provider must have the capability to implement QR-code tracking should the Department elect to implement this approach in the future. Standard carrier tracking alone will not satisfy the QR-code capability requirement if the Department elects to implement QR-code tracking.
21.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 5.3.5. Product, 5.3.5.1., 4	How long does this tracking data need to be available/accessible to the customer, and what specific security/compliance requirements apply?	If the Department implements QR-code tracking, tracking information and related records shall be retained in accordance with the applicable record-retention requirements of the resulting Contract. The PO Terms and Conditions require records related to the Purchase Order to be retained for five years after

Question #	Vendor Name	Solicitation Section	Question	Department Response
				expiration, or longer if required by the applicable General Records Schedule. Applicable confidentiality, data security, and other state and federal requirements also apply.
22.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 5.3.5. Product, 5.3.5.1., 4	What exact fields are required beyond recipient name and distribution zip code?	If implemented, the QR-code capability must be capable of recording the recipient and ZIP code of administration. No additional specific QR-code data fields are prescribed at this time. Any additional requirements applicable to implementation of the QR-code capability will be communicated by the Department if and when the Department elects to implement the capability.
23.	McKesson Medical-Surgical Government Solutions LLC	PUR 1000, 8.f., 15	Would the State please revise the indemnification provision to apply only to third-party bodily injury claims resulting from the Contractor's negligence or willful misconduct?	Refer to the response to **Question #17**.
24.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Terms and Conditions, 5.3.5.5., 4	What are the LTM sales on each line item in the bid?	The Department does not have historical sales information available in a format that can be provided for each line item in the solicitation. Respondents should base pricing on the requirements and pricing methodology contained in the solicitation and Appendix V.
25.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 2, 1	Please clarify the scope of the term "related content".	For purposes of PO Scope of Work **Section 2**, "related content" means content, products, services, or activities that are sufficiently related to the subject matter and objectives of the Emergency Opioid Antagonist Products & Resources procurement to create an actual or potential conflict of interest.
26.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 2, 1	Please clarify the scope of the term "other engagement".	For purposes of PO Scope of Work **Section 2**, "other engagement" includes another contract, agreement, project, or other business engagement involving related content that could create a conflict of interest with the Provider's responsibilities under this Contract.

Question #	Vendor Name	Solicitation Section	Question	Department Response
27.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 3.3, 4.2, 1, 2	Sections 3.3 and 4.2 reference "Alternate Contract Source" agreements. We understand this solicitation is being conducted as a open source competitive procurement and is not being issued under an existing State Term Contract or Alternate Contract Source agreement. Please confirm that these provisions are not applicable to the solicitation and any resulting contract.	This solicitation is being conducted as an open competitive procurement and is not being issued under an existing State Term Contract or Alternate Contract Source agreement. Refer to **Change No. 08**.
28.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 5.2 Equipment, 5.2.1,	As it is not defined within the solicitation, what equipment may be required to fulfill the requirements of this solicitation?	The Provider is responsible for providing all equipment necessary to perform the services required by the PO Scope of Work. The Department does not identify specific Department-furnished equipment. Equipment necessary to support ordering, reporting, shipping, delivery, and other required services is the Provider's responsibility.
29.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 5.3.4.1.4., 4	Please define what the term "Enrolled Distributor classifications" is under the scope of this solicitation	Enrolled Distributor classifications may include community-based organizations, emergency responders, local health departments, educational institutions, and other entities approved and authorized by the Department to receive and distribute Emergency Opioid Antagonist Products under the Overdose Prevention Program.
30.	McKesson Medical-Surgical Government Solutions LLC	PO SOW DCF RFP 2627 020, 8.2 Invoicing, 8.2.1 and 8.2.2, 8	Would the State consider an alternate invoicing approach to consolidated monthly invoices, such as a monthly invoice report?	No. The PO Scope of Work requires consolidated monthly invoices. Separate consolidated invoices are required for the Community Program and the HEROS Program. An alternate report-only format would not replace the required consolidated invoice. The Provider must also submit the applicable proof-of-delivery documentation for all orders with the Invoice Support Documentation accompanying each consolidated invoice.

Question #	Vendor Name	Solicitation Section	Question	Department Response
31.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Terms & Conditions, Section 3. Payment and Fees, A. Payment Invoicing, 1-2	Please confirm that including Contractor's Federal Employer Identification Number (FEIN) on its standard invoice will meet this requirement.	Yes. Including the Provider's FEIN on the standard invoice will satisfy the requirement, provided all other applicable invoice requirements are met.
32.	McKesson Medical-Surgical Government Solutions LLC	Purchase Order Scope of Work, 5.3.3.3, 3	Section 5.3.3.3 requires the Portal to include a "budget tracker by PO." Would the state be amenable to removing the requirement that the Portal include a "budget tracker by PO."	No. The budget tracker by PO is a required feature of the Ordering and Reporting Portal and will not be removed. The portal requirements include a budget tracker by PO, order history, invoice access, reporting, and other specified functionality.
33.	McKesson Medical-Surgical Government Solutions LLC		Would the State allow alternate invoicing and reporting formats? Contractor's internal systems may limit what formats can be produced (i.e., FEIN can be produced on a standard invoice but not on a monthly invoice report).	The Department may accept alternate formats only when the alternate format provides all information required by the solicitation and does not eliminate or modify a mandatory requirement. Respondents remain responsible for satisfying all specified invoice and reporting requirements. An alternate format will not replace the requirement for separate consolidated monthly invoices for the Community Program and HEROS Program or the required Invoice Support Documentation. Refer to the response to **Question #30**.
34.	McKesson Medical-Surgical Government Solutions LLC	RFP 2627 020, APPENDIX V: COST PROPOSAL, 21	Please provide the total quantities ordered during the past twelve (12) months for each product identified in Appendix V.	The Department does not have historical product quantities available in a format that can be provided for each product listed in Appendix V. Respondents should prepare pricing in accordance with the requirements and pricing methodology established in the solicitation and Appendix V. No minimum purchase volume is guaranteed.

Question #	Vendor Name	Solicitation Section	Question	Department Response
35.	McKesson Medical-Surgical Government Solutions LLC		Please provide copies of applicable cited documents as many included website links are broken.	Refer to **Change No. 01**.
36.	The Naloxone Project		For naloxone distributed through this contract, is it possible for shipments to be packaged and sent in quantities of 12 kits per case, or are vendors required to follow a different case quantity or packaging configuration?	The solicitation does not establish a required case quantity or packaging configuration beyond the product specifications identified in the PO Scope of Work. A Provider may package products in quantities such as 12 kits per case, provided the packaging remains compliant with all applicable product, regulatory, shipping, and Contract requirements.
37.	Padagis US, LLC	PO Scope of Work Section 5.3.5.1 Page 4	QR Code: What is the format and structure for the QR code tracking? Will the QR code need to be printed on a state branded box or be a sticker adhered to the outer box? Will DCF place the sticker on the box or is the preference for the manufacturer to determine QR placement? Is there an agency preference for unique QR codes on each box or a common QR code ? Please share an example of a current QR code being utilized.	The Department has not prescribed a specific QR-code format, branding, placement, or whether the QR code must be printed directly on the product packaging. The Provider is responsible to have the capability to implement a QR-code solution should the Department elect to implement this approach in the future. If implemented, the Provider may determine the specific implementation method, provided the required tracking functionality is maintained and applicable laws and regulations are satisfied. Refer to **Change No. 06**.

Question #	Vendor Name	Solicitation Section	Question	Department Response
38.	Padagis US, LLC	PO Scope of Work Section 5.3.5.5 Page 4	Will there will be preference for contractors to provide more than one formulation/presentation of Emergency Opioid Antagonist Product? Will you consider presentations not listed, but available? Example: Intranasal Emergency Opioid Antagonist Product in bulk packaging, rather than 2ct units, for environmental concerns and for the ease of high volume users or those who kit naloxone with other overdose supplies.	The Department does not provide a preference or additional scoring solely for proposing multiple formulations. Respondents may propose one, multiple, or all products listed in Appendix V. Products or presentations not listed in the solicitation will not be considered unless the solicitation is amended.
39.	Padagis US, LLC	DCF RFP 2627 020 Section 5 The Selection Methodology Page 11	In the event this RFP is awarded to more than one manufacture for a single presentation, will DCF award a primary and secondary award?	No primary or secondary award designation is established by the solicitation. The Department reserves the right to make more than one award for the products and services encompassed by the solicitation.
40.	Padagis US, LLC	DCF RFP 2627 020 Section 5 The Selection Methodology Page 11	In the event of multiple awards for a single presentation will DCF award a minimum volume commitment or a % of the total volume business divided among the awarded manufacturers? With an anticipated number of ship-to-locations to each awarded manufacturer.	No minimum volume commitment or percentage allocation is guaranteed to any awarded Provider. The Department anticipates making a minimum of one award per product and reserves the right to make multiple awards.
41.	Amneal Pharmaceuticals	RFP 2.1	If Respondent presentations are requested, will presentations be requested from all Respondents competing for the same product? Please identify whether presentations will be scored, what criteria will apply,	The Department may request Respondent presentations. Presentations are not a separate scored criterion in **Section 5.2.1** and will not independently change the scores assigned to the written Response. If presentations are requested, the Department will provide the applicable Respondents

Question #	Vendor Name	Solicitation Section	Question	Department Response
			whether they may change an existing score, and whether all competing Respondents will receive equivalent presentation instructions and time.	with equivalent instructions and a substantially equivalent opportunity to participate for the applicable product.
42.	Amneal Pharmaceuticals	RFP 2.7.4	Please describe the rationale, criteria, and methodology the Department will use to determine whether more than one award will be made for the 4 mg naloxone formulation, including whether price will be factored into this analysis.	The Department may make multiple awards for a product when determined to be in the best interest of the State. The solicitation does not establish a separate formula for determining the number of awards. Price is considered as part of the overall evaluation, with financial scoring worth up to 40 points.
43.	Amneal Pharmaceuticals	RFP 2.7.4	If multiple awards are made for the 4 mg naloxone HCl nasal spray formulation, please describe the methodology DCF will use to allocate orders and distribution volume among awarded Respondents. To promote fair competition and enable all Respondents to develop pricing using consistent and reasonable volume assumptions, please identify the anticipated allocation methodology (e.g., equal allocation, percentage allocation, rotation, lowest-price priority, performance-based allocation, or another method) and provide the estimated annual and monthly volume, including anticipated peak-month volume, that a Respondent should assume for pricing purposes.	The Department will not establish a fixed percentage, rotation, minimum volume, or other guaranteed allocation methodology among multiple awarded Providers. Orders will be placed based on Department program needs and operational requirements. Respondents should not assume a guaranteed volume when developing pricing.
44.	Amneal Pharmaceuticals	RFP 4.2.6.2-4.2.6.3/SOW 5.1	Please reconcile the 4mg historical requirement to demonstrate delivery to "over 1,300 Enrolled Distributors/addresses" with the current SOW requirement to serve	The shipping history requirements in **Sections 4.2.6.2** and **4.2.6.3** establish the specific competency thresholds for the 4 mg product. Respondents may describe comparable distribution experience where relevant to demonstrating capability; however, the

Question #	Vendor Name	Solicitation Section	Question	Department Response
			approximately 1,500 Enrolled Distributors. Also, many pharmaceutical companies serve comparable high-volume, multi-address pharmaceutical distribution partners. Please clarify that manufacturers that are not currently providing delivery at this level within the State of Florida can provide data on analogous distribution activities.	Response must address the specific requirements established by the solicitation. The current solicitation requires evidence of shipments to more than 1,300 distributors at the specified volume levels, while the SOW's operational requirement is approximately 1,500 Enrolled Distributors.
45.	Amneal Pharmaceuticals	RFP 4.3.1, 5., 5.2	Please clarify whether programmatic and financial evaluations will be performed separately for each product proposed, such that a Respondent's score and ranking for one product will not be affected by requirements or pricing applicable to another product. If not, please describe precisely how Respondents proposing different combinations of products will be evaluated on an equivalent basis.	Yes. Evaluations will be applied on a product-specific basis for each product proposed. The applicable programmatic evaluation criteria will be applied to the Respondent's Response for the product proposed, and the financial evaluation will be calculated separately for each product in accordance with Section 5.2.2. A Respondent's proposed pricing for one product will not be combined with or used to calculate the financial score for another product. Respondents proposing one, multiple, or all products will be evaluated using the same applicable criteria and methodology for each product proposed. Refer to **Change No. 04**.
46.	Amneal Pharmaceuticals	RFP Section 5. The Selection Methodology	Will the Department use artificial intelligence, machine learning, automated scoring, or other AI-enabled tools in any portion of the proposal evaluation, scoring, ranking, or selection process? If so, please describe the role of such tools, including whether they will analyze Respondent-submitted information, and explain the safeguards the Department will use to protect trade	No. All responses will be evaluated by authorized employees of the Florida Department of Children and Families in accordance with the evaluation criteria and methodology established in the solicitation.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			secrets, confidential information, and other legally protected information from unauthorized access, disclosure, retention, or use.	
47.	Amneal Pharmaceuticals	RFP Section 5. The Selection Methodology	Please describe the process, if any, for identifying and addressing material variances among independent evaluator scores for the same Response section (for example, where one evaluator assigns a score of 1 and another assigns a score of 4). Are such scoring variances subject to review, reconciliation, additional documentation, or other procedures intended to ensure that the published evaluation criteria have been consistently applied to all Respondents?	Evaluators will independently evaluate and score each responsive Response using the published evaluation criteria. The solicitation does not establish a separate score-reconciliation or variance-adjustment process. Evaluator scores will be applied in accordance with the product-specific scoring and ranking methodology established in **Section 5.2** and **Change No. 04**.
48.	Amneal Pharmaceuticals	RFP 5.1/5.2.1	Section 5.1 states that the Department "may consider any information" reflecting capability, integrity and reliability. Please clarify what information outside the submitted Response may be considered, how it will be verified, and how a Respondent will know what additional information is considered. How will this additional information be scored in the Programmatic Scoring?	The Department may consider information that reflects upon a Respondent's capability to fully perform the Contract requirements and demonstrates the level of integrity and reliability required to assure performance. Any information considered will be evaluated in accordance with applicable law and the solicitation. The Department may request clarification or supporting documentation when appropriate.
49.	Amneal Pharmaceuticals	RFP 5.2.1 Service Capability	Please identify the relative weighting, points, or evaluator consideration assigned to each sub-criterion within the 8-weight Service Capability criterion, including the two 4mg-only	The solicitation does not establish separate point values or sub-weights for the individual Service Capability considerations. Evaluators will assign a score from 0–4 for the Service Capability criterion as a whole, which carries a weight of 8. The listed

Question #	Vendor Name	Solicitation Section	Question	Department Response
			shipping-history requirements, sample report, staffing plan, general service capability, and product specifications.	considerations will be used to evaluate the Respondent's overall Service Capability.
50.	Amneal Pharmaceuticals	RFP Section 5.2.2 Financial Scoring	Because Respondents may propose one, multiple, or all products, please clarify what constitutes "Lowest costs received for all Responses" (N) and "Respondent's costs" (X). Will the financial formula be calculated separately for each product using the cost per kit/unit for that product, or will prices across multiple proposed products be combined? Without a product-by-product denominator, unlike portfolios may not be financially comparable.	The financial evaluation will be calculated separately for each product. For purposes of the financial evaluation, “Lowest costs received for all Responses” (N) will mean the lowest responsive cost received for that product, and “Respondent’s costs” (X) will mean the Respondent’s proposed cost for that same product. Costs for different products will not be combined for purposes of calculating the financial score for an individual product. Refer to **Change No. 04**.
51.	Amneal Pharmaceuticals	RFP Appendix II	Appendix II's Master Certification references solicitation "DCF RFP 2526 018." Please confirm that this is a typographical error and that Respondents should revise or interpret the certification as referring to DCF RFP 2627 020.	Refer to **Change No. 07.**
52.	Amneal Pharmaceuticals	RFP Appendix V: Cost Proposal	Please confirm whether awards and rankings will be determined independently for each dosage/formulation listed in Appendix V. If a Respondent proposes multiple products, will it receive a separate programmatic score, financial score, total score, and ranking for each proposed product?	Yes. Awards, scores, and rankings will be determined independently for each product proposed. Refer to the response to **Question #45** and **Change No. 04.**
53.	Amneal Pharmaceuticals	SOW 5.3.3.	Does the Department want/need the option of batch/bulk ordering (i.e.	Batch or bulk ordering is not a mandatory portal feature identified in **Section 5.3.3.** Respondents may

Question #	Vendor Name	Solicitation Section	Question	Department Response
			spreadsheet upload and/or submission option)?	describe additional ordering functionality as part of their proposed Project Approach; however, the required portal functionality must be provided regardless.
54.	Amneal Pharmaceuticals	SOW 5.3.1.3	Informational/educational materials in English, Spanish, and Haitian Creole and demonstration devices must be provided at no charge. If more than one award is made, will these materials only be requested in proportion to the Vendor's naloxone distribution?	The Provider must make the required informational and educational materials and demonstrational devices available at no cost as required by the PO Scope of Work. The solicitation does not establish a proportional allocation methodology for these resources among multiple awarded Providers. The Department may determine quantities and distribution needs based on program requirements.
55.	Amneal Pharmaceuticals	SOW 5.3.1.4	Will a shipping company's location of delivery, timestamp of delivery, and typed name of recipient serve as adequate signature for proof of delivery?	The PO Scope of Work requires a signature for proof of delivery. An electronic signature may be acceptable if it constitutes a valid signature associated with the delivery and identifies the person receiving the shipment. Delivery location and timestamp alone, without the required signature or equivalent proof of receipt, would not satisfy the requirement.
56.	Amneal Pharmaceuticals	SOW 5.3.5.1.	Please provide additional clarification on the QR code expectations and functionality. • Is the goal of the QR code to track distribution to an enrolled distributor or to a community-level recipient after an enrolled distributor hands out the naloxone (i.e. naloxone carrier)? Define "specific to services funded under the resulting purchase order." Does this mean different questions for HERO and Community programs or for the DCF program as a whole? Will these questions change over time?	Refer to **Change No. 06**. The Department is not requiring implementation or use of QR-code tracking at this time. The Provider must have the capability to implement QR-code tracking should the Department elect to implement this approach in the future. If implemented by the Department, the intended recipient for tracking purposes would be the organization receiving the naloxone kits from the Provider (e.g., the enrolled distributor), rather than the ultimate individual receiving or administering the naloxone. The Department anticipates that the QR-code capability could be used to capture the ZIP code associated with the location of administration.

Question #	Vendor Name	Solicitation Section	Question	Department Response
				"Specific to services funded under the resulting purchase order" means that information collected through the QR-code capability must relate to Emergency Opioid Antagonist Products and services provided under the resulting purchase order. The Department is not establishing separate QR-code questions or data requirements for the HEROS and Community Programs at this time, and no specific changes to the information collected over time are established. Any additional requirements applicable to implementation of the QR-code capability, including any program-specific or updated data requirements, will be communicated by the Department if and when the Department elects to implement the capability. No additional QR-code-specific data fields or reporting requirements are established at this time. If implemented, the QR-code solution and related records will remain subject to the applicable records-retention, confidentiality, data-security, and other state and federal requirements of the resulting Contract.
57.	Amneal Pharmaceuticals	SOW 5.3.5.1	Please also define "package" for this requirement (case, carton, individual blister pack, or shipment to a distributor). Does the QR code need to be located "on" the "package" or accompany the "package"? Please consider that applicable FDA regulations restrict packaging content, so any packaging changes to comply with this section are subject to FDA approval.	The Department is not requiring implementation or use of QR-code tracking at this time. If the Department elects to implement QR-code tracking, the Provider may determine whether the QR code is applied to product packaging, a kit, shipment materials, or other accompanying materials, provided the required tracking functionality is maintained and all applicable laws and regulations are satisfied. The Department is not requiring a QR code to be printed directly on product packaging.

Question #	Vendor Name	Solicitation Section	Question	Department Response
58.	Amneal Pharmaceuticals	SOW 5.3.5.1	Please clarify whether the QR code must be manufacturer-applied to product packaging, may be Provider-applied to the shipment/kit, or may be supplied as accompanying material. Please also specify whether DCF or the Provider will host and maintain the system that records recipient and distribution ZIP code.	If the Department elects to implement QR-code tracking, the Provider will be responsible for implementing and maintaining the QR-code tracking solution and the system necessary to record the required recipient and ZIP-code information. The Department is not requiring implementation or use of QR-code tracking at this time. The Department has not prescribed whether the QR code must be manufacturer-applied, Provider-applied, or supplied as accompanying material.
59.	Amneal Pharmaceuticals	SOW 5.3.5.1	Define “recipient” for QR-code tracking purposes (e.g., the Enrolled Distributor receiving the shipment, the organization distributing the product, or the ultimate individual receiving the product). Is the recipient the distributor the naloxone is shipped to or the person who naloxone is given to in the community by an enrolled distributor? Is the data intended to be captured when naloxone is received or when naloxone is administered? Identify any expectations for specific required data fields, privacy/security requirements, retention requirements, and the reporting expectations related to the QR code.	Refer to the response to **Question #56.**
60.	Amneal Pharmaceuticals	SOW 5.3.1.5	The SOW states that Emergency Orders typically occur four to six times per month. Is this estimate across the entire program or per awarded Provider/product? Please provide typical emergency-order quantities and destinations so all	The four-to-six Emergency Orders per month is an estimate for the overall program, not a guaranteed volume per awarded Provider or product. The Department does not have typical emergency-order quantities or destination information available for use as a guaranteed pricing assumption. Respondents should not assume a minimum emergency-order volume.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			Respondents can incorporate the same assumptions into pricing.	
61.	Amneal Pharmaceuticals	SOW 6	Please clarify whether the Deliverables, Minimum Performance Measures, and Financial Consequences apply independently to each awarded product/PO or collectively to all products supplied by a Provider, particularly where the Provider receives awards for multiple products.	The Deliverables, Minimum Performance Measures, and Financial Consequences apply to the Provider's performance under the applicable Purchase Order. Where multiple products are included under the same Purchase Order, the applicable financial consequence will be applied as specified in the Deliverables table and based on the applicable invoice/payment amount.
62.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 1.3: Term of the Agreement Page 4 Purchase Order Scope of Work DCF RFP 2627 020 Section 3.1 Page 1	Please confirm that the anticipated contract term is November 20, 2026, through November 19, 2027, as stated in PS Scope of Work Section 3.1.	Yes. Refer to **Change No. 05**.
63.	Emergent Devices Inc	Request for Proposal DCF RFP 2627 020 Section 4.2.6.2 Page 10	Please confirm that, for Section 4.2.6.2, the phrase “at least ten months per year”, coupled with the section’s reference to shipping history within the past 3 years, means that the specified shipping threshold must be demonstrated in at least 10 separate months in each of three consecutive 12-months periods	Yes. For purposes of **Sections 4.2.6.2** and **4.2.6.3**, the Respondent must demonstrate the applicable shipping threshold during at least ten separate months in each of the three 12-month periods immediately preceding the response deadline.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			within the 3 years preceding the response deadline.	
64.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Sections 4.2.6.2 and 4.2.6.3 Page 10	To support supply chain resilience and continuity of supply, will DCF consider the length of time the respondent's offered 4mg product has been continuously manufactured and assembled in the U.S. when assigning the Service Capability score?	The length of time the offered product has been continuously manufactured and assembled in the United States is not a separately weighted evaluation criterion. Respondents may provide this information as supporting information demonstrating their capability, but there are no separate points assigned solely for the duration of U.S. manufacturing.
65.	Emergent Devices Inc	Request for Proposal DCF RFP 2627 020 Sections 4.2.6.2 and 4.2.6.3 Page 10	To support rapid and correct administration in high-stress overdose situations, will DCF confirm that evaluators may consider demonstrated user familiarity, compatibility with existing FL or comparable statewide training materials and demonstrational devices, and the extent to which the offered product reduces retraining, administration errors, or confusion among community users and emergency responders when assigning the Service Capability and Project approach sores? Please confirm that any claimed familiarity or reduced training burden must be supported by documented evidence.	Relevant demonstrated user familiarity, compatibility with existing training materials, and operational advantages may be considered to the extent they demonstrate the Respondent's capability under the published evaluation criteria. Respondents should provide documentation supporting any claimed advantages or reductions in training burden.
66.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Sections 4.2.6.2 and 4.2.6.3 Page 10	Please confirm that, when assigning the Service Capability score under Section 5.2.1, evaluators may consider documented shipping history showing the volume requirements in Sections 4.2.6.2 and 4.2.6.3 were achieved with the same offered 4mg product manufactured	Yes. Documented shipping history involving the offered 4 mg product may be considered in assessing the Respondent's demonstrated capability to meet the Contract requirements, provided the documentation is responsive to the requirements in **Sections 4.2.6.2** and **4.2.6.3.**

Question #	Vendor Name	Solicitation Section	Question	Department Response
		Purchase Order Scope of Work PO SOW DCF RFP 2627 020 Section 5.3.5.2 Page 4	and assembled in the U.S. when assessing the strength of the respondent's proven capability to meet the Contract requirements.	
67.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 4.2.7: Response Section 6: Project Approach Page 10	To strengthen data security, will DCF consider whether all State and program data, including order, reporting, and QR-code data, is stored and backed up only within the U.S. when assigning the Project Approach score?	U.S.-based storage and backup of State and program data is not a separately identified scoring criterion in **Section 5.2.1.** Respondents may identify such practices as part of their Project Approach, and all applicable data security, confidentiality, and other contractual requirements must be satisfied.
68.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 4.2.8: Response Section 7: Prior Similar Projects Page 10	Will the Prior Similar Projects score reflect how closely cited projects mirror the solicitation's core requirements, including achieving the shipping volume requirements in Sections 4.2.6.2 and 4.2.6.3 with the exact offered 4mg product manufactured and assembled in the U.S. and supplying product with at least 30 months of remaining shelf life at shipment?	The similarity and relevance of the projects submitted under **Section 4.2.8** will be considered in determining how well the Respondent demonstrates relevant experience. Projects do not have to involve the exact same product; however, Respondents should demonstrate similarities in scope, scale, distribution, logistics, and other relevant requirements.
69.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic	To reduce administrative burden and streamline contract management, will DCF consider documented efficiencies from a respondent supplying multiple solicited products, including consolidated ordering, reporting, invoicing, and account	Because Responses, scores, and rankings will be evaluated separately for each product, documented efficiencies associated with supplying multiple solicited products may be considered only to the extent they directly demonstrate the Respondent's

Question #	Vendor Name	Solicitation Section	Question	Department Response
		Scoring Pages 12-13	management, when assigning the Service Capability and Project Approach scores?	capability to perform the requirements for the particular product being evaluated. No advantage or additional points will be assigned solely because a Respondent proposes multiple products.
70.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	To ensure consistent application of the published evaluation criteria and compliance with applicable federal and state requirements, will DCF confirm that free product replacement programs, including replacement of expired product, will not be considered in scoring or otherwise increase a respondent's evaluation score?	The Department will evaluate Responses using the published evaluation criteria. Free product replacement programs, including replacement of expired product, will not be considered in scoring or otherwise increase a Respondent's evaluation score.
71.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	Will relevant value-added processes, tools, or operational enhancements that exceed minimum requirements and demonstrably reduce administrative burden or improve operational efficiency be considered and reflected in the Service Capability and Project Approach scores?	Yes. Value-added processes, tools, or operational enhancements may be considered when they demonstrate an innovative, practical, effective, and relevant approach to meeting the published requirements. Any such consideration will occur within the existing evaluation criteria and weights; no additional points outside the published methodology will be awarded.
72.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	Consistent with the Legislature's direction to prioritize timely availability, will DCF consider the length of continuity of the offered product's documented commercial availability at the scale required by this solicitation when assigning the Service Capability score?	The continuity of commercial availability of an offered product is not a separately weighted criterion. Respondents may provide this information as supporting evidence of capability, but it will not receive separate points solely based on the length of commercial availability.

Question #	Vendor Name	Solicitation Section	Question	Department Response
73.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	Aligned with federal efforts to strengthen pharmaceutical supply-chain resilience and prioritize domestically manufactured APIs, will DCF consider the length and continuity of the offered 4mg product's documented use of U.S. manufactured API when assigning the Service Capability score?	The length or continuity of use of U.S.-manufactured API is not a separately weighted evaluation criterion. Respondents may provide this information as supporting information regarding product capability and supply continuity.
74.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	To support sustained Florida economic development, will DCF consider the annual value and continuity of a respondent's documented enterprise-wide purchases from Florida-based suppliers over the past three years as a programmatic evaluation factor?	No. Enterprise-wide purchases from Florida-based suppliers are not identified as a separate evaluation criterion in the solicitation and will not receive separate programmatic points.
75.	Emergent Devices Inc	Request for Proposal DCF RFP 2627 020 Section 5.2.1: Programmatic Scoring Pages 12-13	Appendix II, Respondents Certifications, page 16, identifies solicitation "DCF RFP 2526 018" in the Master Certification. Please issue a correct Appendix II identifying solicitation "DCF RFP 2627 020" and confirm that Respondents must execute and submit the correct Appendix II with their responses. If DCF does not issue a corrected form, please confirm that Respondents may manually correct and initial the solicitation number without affecting the responsiveness of their Responses.	Refer to **Change No. 07**.
76.	Emergent Devices Inc	Request for Proposal DCF RFP 2627 020	Consistent with DCF's previously adopted "Distributor Choice by Product Type" model and this solicitation's stated objective of	The solicitation does not establish a distributor-choice allocation model for multiple awards of the 4 mg product. If multiple awards are made, the Department

Question #	Vendor Name	Solicitation Section	Question	Department Response
		Section 5.2.1: Programmatic Scoring Pages 12-13 Request for Proposal DCF RFP 2627 020 Appendix II: Respondent's Certifications Page 16	promoting access, affordability, and continuity of care, if DCF makes multiple awards for the 4mg product under this solicitation, will DCF continue to permit each enrolled distributor to designate its preferred 4mg product for orders placed on its behalf?	will determine order distribution based on program needs and operational requirements.
77.	Emergent Devices Inc.	Request for Proposal DCF RFP 2627 020 Appendix V: Cost Proposal Page 21	To reduce packaging waste and improve program efficiency, will DCF consider value-added packaging options, including multi-pack configurations or carrying cases, when assigning the Project Approach score?	Respondents may describe value-added packaging options as part of their Project Approach. Any proposed packaging must remain compliant with the product specifications, applicable regulatory requirements, and the pricing methodology established in Appendix V. Such options will not receive separate points outside the published evaluation criteria.
78.	Emergent Devices Inc.	Purchase Order Scope of Work DCF RFP 2627 020 Section 3.4 Page 1 Purchase Order Scope of Work DCF RFP 2627 020 Section 8.3.5 Page 9	Consistent with PO SOW Sections 3.4 and 8.3.5, will DCF consider that requests for new deliverables or services outside the original SOW will be subject to mutually agreed scope, pricing, and a written contract amendment before implementation?	Yes. PO Scope of Work **Section 3.4** provides that additional services may be included or added upon mutual written agreement and through issuance of a change order. **Section 8.3.5** likewise provides that modifications to the PO require mutual written agreement and will be addressed through a change order in MFMP.
79.	Emergent Devices Inc.	Purchase Order Scope of	To clarify standard fulfillment timelines, will DCF confirm that the	Yes. Orders placed by Department staff by 4:00 PM ET on a business day are subject to the two-day

Question #	Vendor Name	Solicitation Section	Question	Department Response
		Work DCF RFP 2627 020 Section 5.3.1.2 Page 2	two-day delivery requirement applies to orders received by 4pm EST Monday through Friday, with standard deliveries occurring Monday through Friday from 8AM to 5pm EST?	shipping requirement. For example, an order placed by 4:00 PM ET on Monday must be delivered by 5:00 PM ET on Wednesday. Standard delivery hours are Monday through Friday, 8:00 AM to 5:00 PM ET, subject to the receiving hours of the Enrolled Distributor.
80.	Emergent Devices Inc.	Purchase Order Scope of Work DCF RFP 2627 020 Section 5.3.1.4 Page 3	Please clarify the Department's expectations regarding delivery attempts and recipient communication. Specifically, if the Provider utilizes a commercial carrier whose standard policy includes a maximum of three delivery attempts before a shipment is returned to sender, will compliance with the carrier's standard delivery process satisfy this requirement? Additionally, what role does the Department envision for Enrolled Distributors in ensuring awareness of signature requirements and availability to receive deliveries?	Yes, provided the Provider remains responsible for satisfying the Contract requirement. The Provider must make a minimum of three redelivery attempts or reroute the shipment, at no additional cost to the Department or Enrolled Distributor. Enrolled Distributors are responsible for providing accurate receiving hours and ensuring that appropriate personnel are available to receive shipments. The Provider must make reasonable efforts to coordinate successful delivery.
81.	Emergent Devices Inc.	Purchase Order Scope of Work DCF RFP 2627 020 Section 5.3.1.5 Page 3	While our organization will make every reasonable effort to fulfill Emergency Orders placed by 4:00 PM EST with overnight delivery, circumstances outside of the Provider's control may occasionally impact delivery timelines. Please clarify whether penalties will be assessed in situations where the Provider has made a good-faith effort and can document it but is unable to meet the specified delivery requirement due to uncontrollable factors.	If a delay qualifies as an excusable delay under the Force Majeure provision of the Purchase Order Terms and Conditions, and the Provider satisfies the required notice provisions, the Provider will not be responsible for the delay to the extent provided in that provision. The Department will evaluate whether the circumstances qualify under the Contract.

Question #	Vendor Name	Solicitation Section	Question	Department Response
82.	Emergent Devices Inc.	Purchase Order Scope of Work DCF RFP 2627 020 Section 5.3.5.1 Page 4	Consistent with the Legislature's direction to prioritize cost-effectiveness and to maximize the value of state and federal funds, will DCF consider shelf life remaining at delivery beyond the 30-month minimum required at shipment when assigning the Service Capability score?	Shelf life beyond the 30-month minimum is not a separately weighted scoring criterion. Respondents may identify additional shelf life as supporting information regarding product capability, but no separate points will be awarded solely for exceeding the minimum requirement.
83.	Emergent Devices Inc	Purchase Order Scope of Work DCF RFP 2627 020 Section 5.3.5.2 Page 4 Purchase Order T&Cs Section 9: Commodities Logistics Page 10	Please confirm that all 4mg products supplied under the Contract must comply with PO SOW Section 5.3.5.2 and that, consistent with the PO Terms & Conditions prohibition on substitutions, product manufactured or assembled outside the U.S. may not be used to fulfill Contract orders, including during a potential supply interruption or inventory transition.	Yes. Products supplied under the resulting Contract must comply with PO Scope of Work Section 5.3.5.2. The products must be manufactured and assembled in the USA from USA and imported components, and the Provider must identify any imported components and their country of origin. Any product supplied must meet the Contract requirements.
84.	Emergent Devices Inc.	Purchase Order Scope of Work DCF RFP 2627 020 Section 8.2.3 Page 9	Section 8.2.3.11 requires the inclusion of "Received By" information as part of the Invoice Support Documentation. Currently, the Provider reports shipment delivery status and delivery date, which have been accepted by the Department and provide confirmation of successful delivery. Will delivery status confirmation (e.g., "Delivered") together with the delivery date satisfy the intent of the "Received By" requirement, or is there additional information the Department	No. A delivery status such as "Delivered" and a delivery date alone do not satisfy the "Received By" requirement. The Invoice Support Documentation must include the "Received By" information and the date delivered, as specified in **Sections 8.2.3.11** and **8.2.3.12.**

Question #	Vendor Name	Solicitation Section	Question	Department Response
			specifically requires to meet this requirement?	
85.	Market Performance Group	Scope of Work – 5.3.5.1	a. "The Provider must enable tracking of distributed kits by including a QR code to accompany each package that records the recipient and the zip code of distribution. Information gathered through the QR code shall be specific to services funded under the resulting purchase order" b. HRT utilizes a third-party logistics provider that maintains comprehensive shipment-level tracking for all orders. Small-parcel shipments are tracked through UPS/FedEx tracking numbers, and LTL shipments are tracked through carrier PRO numbers. Shipment records, including signed Bills of Lading (BOLs) and Proofs of Delivery (PODs), are maintained and can be reported to the Department upon request. c. Question: Would the Department accept this existing shipment-level tracking and reporting capability as an alternative to the QR-code requirement in Section 5.3.5.1, provided the reporting identifies the shipment recipient and destination ZIP code and is specific to products funded under the resulting Purchase Order?	Refer to the response to **Question #20** and **Change No. 06**.

Question #	Vendor Name	Solicitation Section	Question	Department Response
86.	Market Performance Group	Scope of Work 10. Definitions	"Includes but not limited to, stickers, posters, flyers, informational sheets, signs, demonstrational devices, and educational materials, available in English, Spanish, and Haitian Creole. Additional languages may be requested. a. Question: Would the Department accept these educational and informational resources being made readily available electronically through the Provider's website for viewing and/or download in English, Spanish, and Haitian Creole, rather than requiring physical copies of all materials to accompany shipments?	Refer to **Change No. 09**.
87.	Market Performance Group	Scope of Work – 2 day shipping clause	a. Harm Reduction Therapeutics (HRT) is a nonprofit pharmaceutical organization focused on expanding naloxone access at the lowest possible cost. To support this mission, HRT has partnered with Greenwood Brands as its Order-to-Cash provider and Vendor of Record to manage all fulfillment, distribution, and customer operations. Greenwood operates through a centralized 3PL model in partnership with RJW Logistics, with primary distribution out of Chicago, Illinois. This model provides compliant pharmaceutical handling, inventory control, and scalable national distribution while maintaining cost efficiencies aligned with HRT's nonprofit mission. Due to the	No. Refer to the response to **Question #79**.

Question #	Vendor Name	Solicitation Section	Question	Department Response
			centralized warehouse location and HRT's nonprofit operating mode, Greenwood is able to consistently meet a ten (10) calendar day delivery requirement to Florida destinations. b. Question: Would the Department consider revising the standard, non-emergency delivery requirement to allow delivery within ten (10) calendar days of order placement, while maintaining expedited/overnight shipping for emergency orders?	
88.	ACG	Sections 4.2.6 and 4.2.8	May a respondent serve as the prime contractor while using a properly licensed wholesale-distribution subcontractor to supply and distribute the products? If so, will the subcontractor's relevant shipping history and prior similar projects be considered when evaluating Sections 4.2.6 and 4.2.8?	Yes. A Respondent may propose a properly licensed wholesale-distribution subcontractor, subject to the subcontracting requirements and the Department's prior written consent. The Respondent remains responsible for the performance of all subcontracted work. Relevant experience and shipping history of a proposed subcontractor may be considered to the extent it demonstrates the capability of the Respondent's proposed team to satisfy the Contract requirements.